Paclitaxel-Coated Balloon Angioplasty Versus Drug-Eluting Stent in Acute Myocardial Infarction: The REVELATION Randomized Trial

This study sought to assess the efficacy and safety of a drug-coated balloon (DCB) strategy versus drug-eluting stent (DES) in primary percutaneous coronary intervention for ST-segment elevation myocardial infarction (STEMI). In primary percutaneous coronary intervention for STEMI, stenting has prov...

Full description

Saved in:
Bibliographic Details
Published in:JACC. Cardiovascular interventions 2019-09, Vol.12 (17), p.1691-1699
Main Authors: Vos, Nicola S, Fagel, Nick D, Amoroso, Giovanni, Herrman, Jean-Paul R, Patterson, Mark S, Piers, Lieuwe H, van der Schaaf, René J, Slagboom, Ton, Vink, Maarten A
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This study sought to assess the efficacy and safety of a drug-coated balloon (DCB) strategy versus drug-eluting stent (DES) in primary percutaneous coronary intervention for ST-segment elevation myocardial infarction (STEMI). In primary percutaneous coronary intervention for STEMI, stenting has proved to be beneficial with regard to repeat revascularization, but not recurrent myocardial infarction or death, compared with balloon angioplasty alone. A strategy of DCB angioplasty without stenting might abolish the potential disadvantages of stent implantation while reducing the probability of restenosis observed in plain old balloon angioplasty. In the prospective, randomized, single-center REVELATION trial, we compared DCB with DES in patients presenting with STEMI. Patients with a new, nonseverely calcified culprit lesion in a native coronary artery and a residual stenosis of 
ISSN:1876-7605
DOI:10.1016/j.jcin.2019.04.016